A Phase I Study of HER2-Directed CAR T-Cell Therapy for People with Recurrent or Persistent Ependymoma – On Cancer – Memorial Sloan Kettering

Full TitlePhase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma (PBTC-059) (CIRB)Purpose

CAR T-cell therapy is a type of immunotherapy. With CAR T-cell therapy, white blood cells called T cells are removed from the patient, altered in the laboratory to recognize a protein on the patients cancer cells, multiplied to larger numbers, and returned to the patient to find and destroy cancer cells. The treatment is made from the modified T cells.

In this study, researchers are evaluating a CAR T-cell therapy directed toward a protein on cancer cells called HER2. They are assessing this treatment in children, adolescents, and young adults with a brain tumor called an ependymoma that has come back or continued to grow despite prior treatment.

Before patients receive the CAR T cells, they will have conditioning chemotherapy with fludarabine and cyclophosphamide chemotherapy to suppress the immune system and help prepare the body for receiving the CAR T cells. The treatments in this study are given intravenously (by vein).

To be eligible for this study, patients must meet several requirements, including:

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.

See the original post:
A Phase I Study of HER2-Directed CAR T-Cell Therapy for People with Recurrent or Persistent Ependymoma - On Cancer - Memorial Sloan Kettering